Biogen’s Salanersen Wins FDA Breakthrough Therapy Status for Spinal Muscular Atrophy

Biogen said the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to salanersen, its investigational treatment for spinal muscular atrophy.

The company said the designation was supported by exploratory Phase 1b data showing slowing of neurodegeneration and clinically meaningful motor improvements in some children who had previously been treated with gene therapy. Biogen also says salanersen is designed as a once-yearly therapy.

Why it matters

Breakthrough Therapy Designation is reserved for serious conditions where preliminary clinical evidence suggests a substantial improvement over available therapy. The status can help speed development and review of a candidate, although it does not guarantee approval.

Biogen first said in June 2025 that interim Phase 1 data supported advancing salanersen into registrational studies. In March 2026, the company presented additional Phase 1b data in children with SMA previously treated with gene therapy.

The new FDA designation gives salanersen a stronger regulatory profile as Biogen continues its SMA program. The company has not said whether the agency published additional details on the rationale for the designation.

Further updates could come as the registrational program advances and additional clinical data become available.